Fruquintinib capsules | China Drugs List
Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.
- Brand
- Elunate / Fruzaqla
- Medicine type
- Chemical medicine
- Therapeutic area
- Oncology
- Indications recorded in the public source
- Metastatic colorectal cancer: monotherapy for patients previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, and who have received or are unsuitable for anti-VEGF treatment and anti-EGFR treatment (for RAS wild-type disease). Endometrial cancer: with sintilimab for advanced mismatch repair-proficient (pMMR) disease after failure of systemic anticancer therapy, when curative surgery or curative radiotherapy is unsuitable. The endometrial indication has conditional approval based on a surrogate endpoint. Clinical endpoint data are not yet available, and efficacy and safety require further post-approval confirmation. Full approval depends on an ongoing confirmatory randomized controlled trial establishing clinical benefit with fruquintinib plus sintilimab.
- Indication source and scope
- Source date(s): 2025, 2026. Indications transcribed from the public NHSA manufacturer submission; this is not verification of the complete current label.
- Prescribing-information limitations
- Complete official prescribing information obtained. Mainland China label.
- China availability status
- Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- Overseas status
- Japan, United Kingdom: local approval / launch announcements and official price sources obtained. Indications and dates are specified in each price record; other markets not exhaustively reviewed.
- Insurance classification
- Included in national insurance (Category B)
- Insurance edition
- 2025 edition; effective 1 January 2026
- Insurance restrictions
- Restricted to: (1) metastatic colorectal cancer after fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, in patients who have received or are unsuitable for anti-VEGF treatment and anti-EGFR treatment (for RAS wild-type disease); (2) Endometrial cancer: with sintilimab for advanced mismatch repair-proficient (pMMR) disease after failure of systemic anticancer therapy, when curative surgery or curative radiotherapy is unsuitable.
- Insurance period
- 2026-01-01 to 2027-12-31
- Insurance verification notes
- Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.
Sources
- https://m.cnpharm.com/c/2019-07-01/497890.shtml
- https://www.nhsa.gov.cn/module/download/downfile.jsp?classid=0&filename=a32f9f2f3fc046afaf08471f87456ce3.pdf
- https://www.nhsa.gov.cn/attach/Ypsn2025/YPSN202500031/YPSN202500031.pdf
Open the interactive record, public price references and discussions